Spots Global Cancer Trial Database for pmf
Every month we try and update this database with for pmf cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Study of SB939 in Subjects With Myelofibrosis | NCT01200498 | Myeloproliferat... | SB939 | 18 Years - | M.D. Anderson Cancer Center | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | NCT01340651 | Myelofibrosis | Ruxolitinib | 18 Years - | Incyte Corporation | |
| Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib | NCT02226172 | Primary Myelofi... | Glasdegib (PF-0... Placebo | 18 Years - | Pfizer | |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
| Study of SB939 in Subjects With Myelofibrosis | NCT01200498 | Myeloproliferat... | SB939 | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | NCT06343805 | Primary Myelofi... Post-Essential ... Post-Polycythem... PMF PPV-MF PET-MF | AJ1-11095 | 18 Years - | Ajax Therapeutics, Inc. | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis | NCT05044026 | Primary Myelofi... Post-polycythem... Post-essential ... | Jakavi | 18 Years - 120 Years | Novartis | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
